Glaucoma drug Vyzulta, psoriasis remedy Skilarence win insurance benefit

28 January 2022 - The government granted health insurance benefits for Bausch Health Korea’s glaucoma treatment Vyzulta (latanoprostene bunod) and ...

Read more →

Keytruda reimbursement boosts MSD’s R&D of follow-up drug

17 January 2022 - The government’s recognition of MSD’s Keytruda (pembrolizumab) for reimbursement as the first-line therapy for lung cancer ...

Read more →

$421,000 cancer drug Kymriah becomes eligible for reimbursement

14 January 2022 - Novartis’ breakthrough cancer treatment Kymriah (ingredient: tisagenlecleucel), which costs over 500 million won (US$421,000), has become ...

Read more →

Tagrisso, Opdivo fail to get broader reimbursement

25 November 2021 - AstraZeneca Korea’s non-small-cell lung cancer treatment Tagrisso (osimertinib) and Ono Pharma Korea’s immunotherapy Opdivo (nivolumab) failed ...

Read more →

KRPIA raises concern over HIRA’s cost effectiveness evaluation plan

10 November 2021 - Korea Research-based Pharma Industry Association (KRPIA) expressed concerns over HIRA's plan of evaluating a drug’s cost ...

Read more →

Drug pricing tug of war expected over CAR-T therapy Kymriah

14 October 2021 - The world’s first CAR-T therapy, Kymriah (tisagenlecleucel), passed the review of a panel at the Health ...

Read more →

Takeda's ovarian cancer drug Zejula gets expanded insurance benefit

1 October 2021 - Takeda Korea said its ovarian cancer treatment Zejula would receive expanded health insurance coverage as maintenance ...

Read more →

A review of utility measurement methods used in pharmacoeconomic submissions to HIRA in South Korea: methodological consistency and areas for improvement

28 September 2021 -  This study, which was conducted as part of a project for revision of the pharmacoeconomic ...

Read more →

Will price of Avastin, staple in anti-cancer therapy, go down?

27 September 2021 - Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) inhibitor, is almost a staple in anticancer treatment ...

Read more →

Manufacturers’ perceptions of the decision-making process for new drug reimbursement in South Korea

17 September 2021 - This study aimed to evaluate manufacturers’ perceptions of the decision-making process for new drug reimbursement and to ...

Read more →

Insurance benefits for Pfizer’s heart drug Vyndamax uncertain

9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s ...

Read more →

Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer

7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor ...

Read more →

Acute myeloid leukaemia drug Xospata nears getting insurance benefits

3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step ...

Read more →

Pfizer’s acromegaly treatment receives reimbursement

2 September 2021 - Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, ...

Read more →

CAR-T therapy Kymriah fails to get insurance benefits

2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...

Read more →